Incyte Corporation reported a strong Q4 2025 revenue of $1.51 billion, a 28% increase from the previous year, despite a mixed market reaction that saw the stock decline to $101.68. While the company's impressive earnings surpassed Wall Street expectations and positioned it as a top immunotherapy investment, the stock dipped over 8% earlier due to disappointing sales guidance for its drug Opzelura. Analysts maintain a 'Moderate Buy' rating as Incyte anticipates significant growth, particularly with expected sales surge for Jakafi and new collaborations with industry leaders like Novartis and Eli Lilly.
Loading timeline…
